Fallopian Tube News and Research

RSS

Preventive oophorectomy reduces risks of ovarian, breast cancers in women with BRCA mutation

Women who carry a BRCA gene mutation and opt for a preventive oophorectomy, or ovary removal surgery, have a 77 per cent lower risk of death than those who do not, according to a new study led by Women's College Hospital's Amy Finch and Dr. Steven Narod.

26 Feb 2014

Study: Women with BRCA1 mutations should have preventive ovarian surgery by age 35

The findings of a large international prospective study published in the Journal of Clinical Oncology suggest for the first time that women with BRCA1 mutations should have preventive ovarian surgery (prophylactic oophorectomy) by age 35, as waiting until a later age appears to increase the risk of ovarian cancer before or at the time of the preventive surgery.

25 Feb 2014

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

19 Feb 2014

Researchers discover why women with BRCA gene develop breast and ovarian cancer

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.

17 Oct 2013

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Precision Therapeutics, a leading life-science company dedicated to the improvement of patient outcomes in personalized medicine, today announced findings that support the ChemoFx chemoresponse assay as a tool to aid in the identification of platinum resistance in primary ovarian cancer, according to a presentation at the Annual Meeting of The Western Association of Gynecologic Oncologists June 26-29, in Seattle, Washington.

8 Jul 2013

New research sheds light on successful ovulation and fertilization

Eggs take a long time to produce in the ovary, and thus are one of a body's precious resources. It has been theorized that the body has mechanisms to help the ovary ensure that ovulated eggs enter the reproductive tract at the right time in order to maximize the chance of successful fertilization.

18 Apr 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Answers to the questions of stem cells

Next week, more than 1,200 people from 25 countries are expected to attend the 8th Annual World Stem Cell Summit in West Palm Beach, Fla., a gathering co-sponsored by Mayo Clinic. As those close to the science explore potential stem cell applications, many patients have questions about what stem cells are and how they are being used. Timothy Nelson, M.D., Ph.D., director of Mayo Clinic's Regenerative Medicine Consult Service, answers some of the most commonly asked questions about stem cells.

29 Nov 2012

Researchers develop safe, feasible and robust co-culture system for hESC expansion

Researchers in Taiwan have developed a "safe, feasible and robust co-culture system" supplied by human umbilical cord mensenchymal stem cells (HUCMSCs) to feed the sustained culture used for human embryonic stem cell (hESC) expansion prior to cell transplantation.

17 Nov 2012

Scientists dissect how sperm cells of the fruit fly build their flagella

Sperm swim, lung cells sweep mucus away, and the cells in the female Fallopian tube move eggs from the ovary to the uterus. Underlying these phenomena are flagella - slender, hair-like structures extending from the surface of the cells, that bend, beat or wave rhythmically. In the latest issue of the journal Developmental Cell, scientists from the Instituto Gulbenkian de Ciência (IGC), in Portugal, have dissected how sperm cells of the fruit fly build their flagella.

14 Aug 2012

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012

Cigarette smoke reduces production of Fallopian tube gene - BAD

Cigarette smoke reduces the production of a Fallopian tube gene known as "BAD", which helps explain the link between smoking and ectopic pregnancy. The finding, from scientists led by Drs Andrew Horne and Colin Duncan at the Medical Research Council (MRC) Centre for Reproductive Health in Edinburgh, UK, was described today at the annual meting of ESHRE (European Society of Human Reproduction and Embryology) in Istanbul.

4 Jul 2012

Women with IBS more likely to suffer from ectopic pregnancies, miscarriages

A study by researchers at University College Cork, Ireland and the University of Manchester, UK suggests that women with Irritable Bowel Syndrome are more likely to suffer from miscarriages and ectopic pregnancies.

4 Apr 2012

Scientists discover that sperm do not function like olfactory cells

According to a 2003 study by German and American scientists, a component of the Lily of the Valley scent known as Bourgeonal alters the calcium balance of human sperm and attracts the sperm. The "Lily of the Valley phenomenon" - also the title of a book about smelling - was born as a result of this discovery that sperm act as swimming olfactory cells which follow a "scent trail" laid by the egg. However, a detailed explanation for the Lily of the Valley phenomenon remained illusive as neither Bourgeonal nor other scents could be identified in the female sex organ.

29 Feb 2012

Avastin fails to live up to expectations for extending survival in ovarian cancer

Cancer drug Avastin has been found to add about four months to the time it takes for the cancer to worsen for women with advanced cases of ovarian cancer says a new report. However it may not extend survival significantly.

29 Dec 2011

BROCA test identifies 12 gene mutations linked to ovarian and related cancers

More patients with ovarian carcinoma carry cancer-predisposing mutations, and in more genes, than previously thought.

27 Oct 2011

Caffeine reduces women's chances of becoming pregnant

Caffeine reduces muscle activity in the Fallopian tubes that carry eggs from a woman's ovaries to her womb. "Our experiments were conducted in mice, but this finding goes a long way towards explaining why drinking caffeinated drinks can reduce a woman's chance of becoming pregnant," says Sean Ward, professor of physiology and cell biology, at the University of Nevada School of Medicine, who conducted the study.

21 Jul 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.